{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma+Multiforme+%28GBM%29&page=3", "query": { "condition": "Glioblastoma Multiforme (GBM)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 1344, "total_pages": 135, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma+Multiforme+%28GBM%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioblastoma+Multiforme+%28GBM%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T06:11:59.535Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00047281", "title": "Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "celecoxib", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2004-03", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2017-07-11", "last_synced_at": "2026-10-07T06:11:59.535Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00047281" }, { "nct_id": "NCT00329719", "title": "Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Neoplasm" ], "interventions": [ { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Sorafenib Tosylate", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2006-03-24", "completion_date": "2013-02-02", "has_results": true, "last_update_posted_date": "2018-10-16", "last_synced_at": "2026-10-07T06:11:59.535Z", "location_count": 190, "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Hartford, Connecticut + 118 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT00329719" }, { "nct_id": "NCT00436436", "title": "O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "O6-benzylguanine", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 12, "start_date": "2006-11-13", "completion_date": "2010-04-14", "has_results": true, "last_update_posted_date": "2017-03-28", "last_synced_at": "2026-10-07T06:11:59.535Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436436" }, { "nct_id": "NCT03971734", "title": "Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "High Grade Glioma", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Glioblastoma" ], "interventions": [ { "name": "Regadenoson 0.05mg", "type": "DRUG" }, { "name": "Regadensoson 0.1mg", "type": "DRUG" }, { "name": "Regadensoson 0.2mg", "type": "DRUG" }, { "name": "Regadensoson 0.4mg", "type": "DRUG" }, { "name": "Regadensoson 0.7mg", "type": "DRUG" }, { "name": "Regadensoson 1.0mg", "type": "DRUG" }, { "name": "Regadensoson 1.4mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 7, "start_date": "2019-12-06", "completion_date": "2023-10-02", "has_results": false, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-10-07T06:11:59.535Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Winston-Salem, North Carolina", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03971734" }, { "nct_id": "NCT02704858", "title": "Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Perillyl alcohol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neonc Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2017-08-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-07T06:11:59.535Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Santa Monica, California + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02704858" }, { "nct_id": "NCT05095376", "title": "Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Lomustine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Photon Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 265, "start_date": "2022-03-28", "completion_date": "2031-02-12", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-07T06:11:59.535Z", "location_count": 418, "location_summary": "Fairbanks, Alaska • Fayetteville, Arkansas • Little Rock, Arkansas + 304 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05095376" }, { "nct_id": "NCT07225621", "title": "Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "GBM" ], "interventions": [ { "name": "5-ALA HCl + LIDU SDT", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo + Sham SDT", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Alpheus Medical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 103, "start_date": "2026-01-28", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-07T06:11:59.535Z", "location_count": 11, "location_summary": "Boston, Massachusetts • Rochester, Minnesota • Albany, New York + 6 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Albany", "state": "New York" }, { "city": "Buffalo", "state": "New York" }, { "city": "Long Island City", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07225621" }, { "nct_id": "NCT01856933", "title": "BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "GBM", "Glioblastoma Multiforme", "Gliosarcoma" ], "interventions": [ { "name": "PSMA ADC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Heinrich Elinzano, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2013-05", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2021-11-23", "last_synced_at": "2026-10-07T06:11:59.535Z", "location_count": 2, "location_summary": "Providence, Rhode Island • Dallas, Texas", "locations": [ { "city": "Providence", "state": "Rhode Island" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01856933" }, { "nct_id": "NCT03551249", "title": "Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Glioma", "Glioblastoma" ], "interventions": [ { "name": "Focused ultrasound (FUS)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "InSightec", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2019-03-26", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-10-07T06:11:59.535Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Charlottesville, Virginia + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Charlottesville", "state": "Virginia" }, { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03551249" }, { "nct_id": "NCT03782415", "title": "Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma", "Recurrent Glioblastoma", "GBM", "Newly Diagnosed Glioblastoma" ], "interventions": [ { "name": "MN-166", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MediciNova", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2018-12-29", "completion_date": "2023-08-07", "has_results": false, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-10-07T06:11:59.535Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03782415" } ] }